.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EM04_Duvelisib.Duvelisib .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EM04_Duvelisib.Duvelisib| name: | Duvelisib | |
| ATC code: | L01EM04 | route: | oral |
| compartments: | 1 | |
| dosage: | 25 | mg |
| volume of distribution: | 28.5 | L |
| clearance: | 3.2 | L/h |
| other parameters in model implementation | ||
Duvelisib is an oral dual inhibitor of phosphoinositide 3-kinase delta and gamma (PI3K-δ and PI3K-γ) isoforms. It is approved for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma after at least two prior therapies.
Pharmacokinetic parameters reported following oral administration of duvelisib (25 mg twice daily) in adult cancer patients, including CLL/SLL.